These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

824 related items for PubMed ID: 9028549

  • 1. The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon.
    Gryn J, Johnson E, Goldman N, Devereux L, Grana G, Hageboutros A, Fernandez E, Constantinou C, Harrer W, Viner E, Goldberg J.
    Bone Marrow Transplant; 1997 Feb; 19(3):221-6. PubMed ID: 9028549
    [Abstract] [Full Text] [Related]

  • 2. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR, Mangan KF, Glenn LD, Malaspina DR, Cropper T, Mullaney M, Macdonald JS.
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [Abstract] [Full Text] [Related]

  • 3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 4. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K, Margolin K, Champlin R, Forman S.
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [Abstract] [Full Text] [Related]

  • 5. Immune modulation in autologous bone marrow transplantation: cyclosporine and gamma-interferon trial.
    Vogelsang G, Bitton R, Piantadosi S, Altomonte V, Horn T, Jones R, Miller C, Marcellus D, Abrams R, Hess A.
    Bone Marrow Transplant; 1999 Sep; 24(6):637-40. PubMed ID: 10490729
    [Abstract] [Full Text] [Related]

  • 6. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Chen CI, Roitman D, Tsang R, Stewart AK, Keating A, Crump M.
    Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
    [Abstract] [Full Text] [Related]

  • 7. Second autologous transplant with cyclosporin/interferon alpha-induced graft versus host disease for patients who have failed first-line consolidation.
    Streetly M, Kazmi M, Radia D, Hoyle C, Schey SA.
    Bone Marrow Transplant; 2004 Jun; 33(11):1131-5. PubMed ID: 15094743
    [Abstract] [Full Text] [Related]

  • 8. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ, Taylor PR, Angus B, Wood K, Lennard AL, Lucraft H, Carey PJ, Stark A, Iqbal A, Haynes A, Russel N, Leonard RC, Culligan D, Conn J, Jackson GH.
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [Abstract] [Full Text] [Related]

  • 9. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S, Kirsch A, Schwaner I, Kingreen D, Schwella N, Huhn D, Siegert W.
    Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
    [Abstract] [Full Text] [Related]

  • 10. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
    Dann EJ, Daugherty CK, Larson RA.
    Bone Marrow Transplant; 1997 Sep; 20(5):369-74. PubMed ID: 9339751
    [Abstract] [Full Text] [Related]

  • 11. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
    Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL.
    N Engl J Med; 1995 Dec 07; 333(23):1540-5. PubMed ID: 7477169
    [Abstract] [Full Text] [Related]

  • 12. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study.
    Snyder MJ, Johnson DB, Daly MB, Giguere JK, Harman GH, Harden EA, Johnson RA, Leff RS, Mercier RJ, Messerschmidt GL.
    Bone Marrow Transplant; 1994 Oct 07; 14(4):595-600. PubMed ID: 7858534
    [Abstract] [Full Text] [Related]

  • 13. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
    Dawson LA, Saito NG, Ratanatharathorn V, Uberti JP, Adams PT, Ayash LJ, Reynolds CM, Silver SM, Schipper MJ, Lichter AS, Eisbruch A.
    Int J Radiat Oncol Biol Phys; 2004 May 01; 59(1):208-18. PubMed ID: 15093918
    [Abstract] [Full Text] [Related]

  • 14. Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma.
    Stein RS, Greer JP, Goodman S, Brandt SJ, Morgan DS, Macon WR, McCurley TL, Wolff SN.
    Bone Marrow Transplant; 2000 Feb 01; 25(3):257-62. PubMed ID: 10673696
    [Abstract] [Full Text] [Related]

  • 15. Treatment of refractory lymphoma with high dose cytarabine, cyclophosphamide and either TBI or VP-16 followed by autologous bone marrow transplantation.
    Broun ER, Tricot G, Akard L, Nichols C, Cheerva A, Jansen J.
    Bone Marrow Transplant; 1990 May 01; 5(5):341-4. PubMed ID: 2190660
    [Abstract] [Full Text] [Related]

  • 16. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
    Wadhwa PD, Fu P, Koc ON, Cooper BW, Fox RM, Creger RJ, Bajor DL, Bedi T, Laughlin MJ, Payne J, Gerson SL, Lazarus HM.
    Biol Blood Marrow Transplant; 2005 Jan 01; 11(1):13-22. PubMed ID: 15625540
    [Abstract] [Full Text] [Related]

  • 17. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.
    Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, Colombat P, Goldstone AH, Gorin NC, Flesh M.
    N Engl J Med; 1987 Jun 11; 316(24):1493-8. PubMed ID: 3295541
    [Abstract] [Full Text] [Related]

  • 18. Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas.
    Mabed M, Al-Kgodary T.
    Bone Marrow Transplant; 2006 Apr 11; 37(8):739-43. PubMed ID: 16501587
    [Abstract] [Full Text] [Related]

  • 19. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma.
    de Lima M, van Besien KW, Giralt SA, Khouri IF, Mehra R, Andersson BS, Przepiorka D, Gajewski JL, Korbling M, Champlin RE.
    Bone Marrow Transplant; 1997 Jan 11; 19(2):121-7. PubMed ID: 9116608
    [Abstract] [Full Text] [Related]

  • 20. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
    Law LY, Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R, Shizuru JA, Blume KG, Negrin RS, Stockerl-Goldstein KE.
    Biol Blood Marrow Transplant; 2006 Jul 11; 12(7):703-11. PubMed ID: 16785059
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.